Skip to main content
OpenTrials

Clinical trial condition

High-grade B-cell Lymphoma

Explore clinical trials studying High-grade B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

37 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

High-grade B-cell Lymphoma trial results

Active, Not Recruiting

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841

Conditions
Follicular Lymphoma Grade 3B, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • Sun Yat-sen University Cancer Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 13 locations
View Trial Details
Active, Not Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

NCT05263583

Conditions
Burkitt Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, +24 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Sun Yat-sen University Cancer Center Guangzhou, China
  • Henan Cancer Hospital Henan, China
  • Shanghai East Hospital Pudong, China
View Trial Details
Active, Not Recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

NCT04914741

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +10 more
Locations
  • Concord Repatriation General Hospital Camperdown, New South Wales, Australia
  • St Vincent's Public Hospital Sydney Darlinghurst, New South Wales, Australia
  • Calvary Mater Newcastle Newcastle, New South Wales, Australia
  • Prince of Wales Hospital Randwick, New South Wales, Australia
View all 15 locations
View Trial Details
Active, Not Recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

NCT03620578

Conditions
BCL-2 Translocation, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • BE-Antwerpen-ZNASTUIVENBERG Antwerp, Belgium
  • BE-Leuven-UZLEUVEN Leuven, Belgium
  • NL-Den Bosch-JBZ 's-Hertogenbosch, Netherlands
  • NL-Almere-FLEVOZIEKENHUIS Almere Stad, Netherlands
View all 24 locations
View Trial Details

Related conditions